In a new milestone, SynGAP Research Fund (SRF) is proud to announce an exciting update that marks a new chapter in our ongoing efforts to find a cure for SYNGAP1-related disorders (SRD). Following the trail blazed by other successful rare disease groups like the Foundation for Angelman Syndrome Therapeutics (FAST) (@cureAngelman), the Dravet Syndrome Foundation (@cureDravet), the STXBP1 Foundation (@cureSTXBP1), and numerous other groups such as @cureSMA, @cureKCNH1, cureGM1, @cureCHD2, @cureSHANK, @cureGABAa, @cureGRIN, @cureRareDisease, etc., SRF is now officially using the name “Cure SYNGAP1” complete with the social handle @cureSYNGAP1 and website www.CureSYNGAP1.org.
A Unified Identity Across Platforms
In an effort to streamline our online presence and make it easier for families, researchers, and supporters to connect with us, we have unified all of our social media handles across Twitter, LinkedIn, Instagram, and Facebook to @cureSYNGAP1. This move is not just a rebranding effort, but also a reflection of our laser-focused mission. For many in our community, @cureSYNGAP1 is synonymous with who we are and what we stand for.
Today, we are proud to announce that we have officially filed a “Doing Business As” (DBA) for Cure SYNGAP1. This formal step reinforces our commitment to finding a cure for SYNGAP1 mutations and reflects the evolution of our organization’s identity as we move forward.
What This Means for the Future
Going forward, in addition to the familiar SynGAP Research Fund (SRF) name, you will increasingly see and hear us referred to as “Cure SYNGAP1.” This includes all our communications, outreach efforts, and advocacy work. In fact, in our most recent press release, you may have already noticed the shift, with SRF being referred to as Cure SYNGAP1.
The decision to move forward with this DBA is part of our broader strategy to emphasize the urgent need for a cure. As an organization driven by a passionate community of families, researchers, and advocates, we believe this unified approach will sharpen our focus and amplify our message.
What Doesn’t Change: Our Dedication
While our name might be evolving, our mission remains unchanged: to accelerate the science necessary to find treatments and, ultimately, a cure for SYNGAP1-related disorders. Cure SYNGAP1, as we will now often be called, continues to represent the same values, the same tireless work ethic, and the same dedication to the families affected by this rare genetic condition.
We are deeply grateful to everyone who has been part of our journey so far, and we look forward to continuing to work together toward a brighter future for all SYNGAP1 families.
Stay tuned as we continue to make strides in research, collaboration, and awareness, now with Cure SYNGAP1 leading the charge.
Thank you for your ongoing support, and welcome to this exciting new chapter.